GSK股价下跌,FDA专家组拒绝批准血癌药物Blenrep

英为财情
Jul 18, 2025

Investing.com - GSK Plc (NYSE:GSK)股价下跌5%,此前美国食品药品监督管理局(FDA)咨询专家组投票反对推荐批准该公司的血癌药物Blenrep,理由是认为其风险大于收益。 FDA肿瘤药物咨询委员会以5比3的投票结果反对Blenrep与通用癌症药物Velcade的组合疗法,并以更强烈的7比1的投票结果拒绝将其与百时美施贵宝公司(Bristol Myers Squibb...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10